An Evaluation of a Collagen Dressing to Treat Chronic, Stalled Lower-extremity Wounds

Wound Clinical Trial

Official title:

A Case Series Evaluating a Fibrillar Collagen Powder Dressing to Treat Chronic, Stalled Lower-extremity Wounds

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03723603
• Other study ID #: MED-2018-DIV71-018
• Status: Terminated
• Phase: N/A
• Start date: November 9, 2018
• Est. completion date: July 30, 2019

Study information

• Verified date: February 2020
• Source: Medline Industries
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients who meet the inclusion criteria will be provided with fibrillar collagen powder dressing. The powder dressing will be used in accordance with its label. After cleansing the wound by the clinical site staff, the powder is placed directly on the wound, and then the wound will be covered with an appropriate moisture retentive secondary dressing. Patients will visit the clinic twice a week to have the powder re-applied. Wound evaluations will take place once a week at the outpatient clinic, with the intervention lasting up to twelve weeks. Concurrent standard of care, such as compression for venous ulcers, will be provided.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: July 30, 2019
• Est. primary completion date: June 4, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Has one of the following types of wounds below the knee: diabetic ulcers, pressure ulcers, venous ulcers, ulcers of mixed-vascular origin, traumatic wounds, or post-surgical wounds

• Wound has been present for at least four weeks

• Wound is free of necrotic tissue or debridement practices will take place prior to initial visit in order to remove necrotic tissue

• Wound has failed at least one wound care treatment

• Wound size is between 1 and 100 square centimeters

• Patient has adequate circulation as demonstrated by biphasic or triphasic Doppler waveform, measured within three months prior to study enrollment. If monophasic on exam, then non-invasive tests must display Ankle Brachial Index greater than 0.8 and no worse than mild disease on segmental pressures.

• Wound is confirmed as being free of infection and absence of osteomyelitis

Exclusion Criteria:

• Pregnant, planning to become pregnant during the study timeframe, or breast feeding

• Unable or unwilling to receive porcine collagen

• Wound is infected or presence of osteomyelitis

• Allergy or sensitivity to collagen

• Inability, in the opinion of the Investigator to follow protocol requirements, attend follow up visits in a timely manner, or otherwise comply with the requirements of the protocol

Related Conditions & MeSH terms

• Wound
• Wounds and Injuries

Intervention

Device:
• Fibrillar collagen powder dressing
A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.

Locations

Country	Name	City	State
United States	Cleveland Foot and Ankle Clinic	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Medline Industries

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Wound Size Over Twelve Week Period		Baseline to 84 days
Secondary	Change in Bates-Jensen Wound Assessment Tool	The Bates-Jensen Wound Assessment tool score will be used to assess the wound's status throughout the study. The Bates-Jensen Wound Assessment tool measures wound status. The wound size score ranges from 0 to 5. The wound depth score ranges from 0 to 5. The wound edge score ranges from 0 to 5. The wound undermining score ranges from 0 to 5. The necrotic tissue type score ranges from 1 to 5. The necrotic tissue amount ranges from 1 to 5. The exudate type score ranges from 1 to 5. The exudate amount score ranges from 1 to 5. The skin color surrounding wound score ranges from 1 to 5. The peripheral tissue edema score ranges from 1 to 5. The peripheral tissue induration score score ranges from 1 to 5. The granulation tissue score ranges from 1 to 5. The epithelialization score ranges from 1 to 5. The total score from these sub-scores added together is used as the total BWAT score. For all sub-score values, a value of 0 or 1 is a better outcome.	Baseline to 84 days
Secondary	Change in Reported Pain Level	The pain score will be recorded with a verbal numeric pain rating scale from 0-10.	Baseline to 84 days